Results 121 to 130 of about 105,478 (251)

Cancer pain: current practice and emerging targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye   +5 more
wiley   +1 more source

Phase II study of magrolimab combination therapies in patients with head and neck squamous-cell carcinoma. [PDF]

open access: yesESMO Open
Colevas AD   +19 more
europepmc   +1 more source

Aspartate Transporter SLC1A3 Promotes Colorectal Cancer via MDM2‐p53 Pathway and M2 Macrophage Polarization

open access: yesCancer Science, EarlyView.
SLC1A3 promotes colorectal cancer progression by transporting extracellular aspartate into tumor cells, thereby activating the PKC/MDM2/p53 pathway to enhance proliferation. Reduced extracellular aspartate, combined with p53‐dependent suppression of CSF2 and IL17C, drives M2 macrophage polarization via immune modulation, macrophage recruitment, and M2 ...
Chao Deng   +9 more
wiley   +1 more source

Isoquercitrin Alleviates 5-Fluorouracil-Induced Intestinal Mucositis in Mice by Modulating Inflammation and Oxidative Stress. [PDF]

open access: yesChem Biodivers
Fideles LS   +8 more
europepmc   +1 more source

Relationship Between PTBP1 and Pancreatic Cancer Based on microRNA and Behavior During TYMS‐Mediated Carcinogenesis

open access: yesCancer Science, EarlyView.
Corresponding Author and colleagues identify a pancreas‐enriched microRNA, miR‐216b‐5p, that suppresses PTBP1 and its downstream effector TYMS. Their findings reveal a novel miR‐216b‐5p/PTBP1/TYMS regulatory axis driving pancreatic cancer progression and establish PTBP1 as a central molecular regulator of tumor biology beyond its metabolic role ...
Shigenori Suzuki   +14 more
wiley   +1 more source

Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study). [PDF]

open access: yesInt J Cancer
What's New? Pancreatic cancer often is diagnosed at advanced stages. As a result, treatment regimens frequently are aggressive, with substantial side effects that impact quality of life (QoL). This study examined the treatment landscape, from neoadjuvant therapy to palliative care, in the context of QoL among pancreatic cancer patients in Germany. Most
Goetze TO   +19 more
europepmc   +2 more sources

Top 5 Advances in the Last 50 Years: Malignant Gastric and Esophageal Surgery

open access: yes
World Journal of Surgery, EarlyView.
Luís Santos Castro, Lorenzo Ferri
wiley   +1 more source

Long‐term disease control of disseminated superficial actinic porokeratosis (DSAP) with simvastatin 2%/ cholesterol 2% cream

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Introduction Disseminated superficial actinic porokeratosis (DSAP) is a rare keratinization disorder associated with an increased risk of cutaneous tumors. Objectives To develop a feasible and easy‐to‐apply treatment regimen for long‐time disease control of DSAP including prevention of new skin tumors. Patients and Methods 19 patients with DSAP
Berenice M. Lang   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy